TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19545929

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m² on day 1 and pemetrexed 500 mg/m² followed by gemcitabine 1250 mg/m² on day 8 of a 3-week cycle (GA arm)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Paclitaxel 120 mg/m² followed by gemcitabine 1000 mg/m² on days 1 and 8 of a 3-week cycle (PG arm)
Number of subjects: 105
Study: 18974515

Group type: EXPERIMENTAL
Intervention: Two hours occlusion therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Four hours occlusion therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Six hours occlusion therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Full-time occlusion therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mild to moderate amblyopia (vision 20/30 to 20/80)
Number of subjects: 100
Study: 16828460

Group type: EXPERIMENTAL
Intervention: 1-day behavioral group treatment (BGT) program
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2-day cognitive-behavioral group treatment (CBGT) program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waiting list (WL) control group
Number of subjects: 150
Study: 12798560

Group type: EXPERIMENTAL
Intervention: Lowest quintile of serum hematocrit (Hct) (range 25.4% to 37.5%)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Each 1% decrease in Hct within the lowest quintile
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Higher quintiles of Hct (not specified)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Lower Hct
Number of subjects: 1130
Study: 11139926

Group type: EXPERIMENTAL
Intervention: BS45D lead model
Number of subjects: 30

Group type: COMPARATOR
Intervention: S84F lead model
Number of subjects: 30

Group type: COMPARATOR
Intervention: S44F lead model
Number of subjects: 30
Study: 8970857

Group type: EXPERIMENTAL
Intervention: Preparatory information (procedural, sensory, and coping information) with written support
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (routine advice and support from ward, medical and nursing staff)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Preparatory information (various types and forms)
Number of subjects: 82
Study: 1360452

Group type: EXPERIMENTAL
Intervention: Combination FSH/hMG
Number of subjects: 5

Group type: COMPARATOR
Intervention: hMG only
Number of subjects: 5
Study: 2936353

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 29666901

Group type: EXPERIMENTAL
Intervention: Subcutaneous dexmedetomidine (1 μg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (1 μg/kg)
Number of subjects: 10
Study: 27223147

Group type: EXPERIMENTAL
Intervention: Plasma-derived factor VIII
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII
Number of subjects: 264
Study: 25531119

Group type: EXPERIMENTAL
Intervention: 3.0 mEq/l dialysate calcium
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2.5 mEq/l dialysate calcium
Number of subjects: 56
Study: 22032797

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audio
Number of subjects: 0
Study: 20308817

Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil (group S)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Propofol/remifentanil (group P)
Number of subjects: 302
Study: 18280787

Group type: EXPERIMENTAL
Intervention: Automatic Problem List (APL) system
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (standard problem list management)
Number of subjects: 247
Study: 15772402

Group type: EXPERIMENTAL
Intervention: 1-hour educational intervention (N=18)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (N=14)
Number of subjects: 32
Study: 12725416

Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2 mg/dienogest 2 mg (E2V/DNG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both interventions (E2V/DNG and E2/NETA)
Number of subjects: 45
Study: 10572887

Group type: EXPERIMENTAL
Intervention: Transscleral diode laser coagulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transpapillary diode laser photocoagulation
Number of subjects: 30
Study: 8609551

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1202
Study: 1655056

Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g in a single dose
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg in a single dose on day 1 followed by 250 mg once daily for 2 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Doxycycline 200 mg in a loading dose followed by 100 mg every 12 h for 7 days
Number of subjects: 62
Study: 6820887

Group type: EXPERIMENTAL
Intervention: Futraful (more than 60 g)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Method II (large dose MMC) plus Futraful
Number of subjects: 1673

Group type: COMPARATOR
Intervention: Group A (without Futraful)
Number of subjects: 1673
Study: 29532291

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg kg-1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL) 6 mg kg-1 of maltodextrin
Number of subjects: 30
Study: 28130432

Group type: EXPERIMENTAL
Intervention: Azithromycin (2 g)
Number of subjects: 829
Study: 25811544

Group type: EXPERIMENTAL
Intervention: L-glutamine (0.3 g·kg‐1·day‐1 + 0.3 g·kg‐1·day‐1 maltodextrin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L-glutamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 0.6 g·kg‐1·day‐1)
Number of subjects: 16
Study: 24092942

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering regimens (various drug classes including ACE inhibitors, calcium antagonists, diuretics/β blockers)
Number of subjects: 152290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152290
Study: 22146628

Group type: EXPERIMENTAL
Intervention: Ligustrazine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Kakonein
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Panax Notoginsenoside
Number of subjects: 144

Group type: COMPARATOR
Intervention: Model Control
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All Treated Groups
Number of subjects: 144
Study: 19153290

Group type: EXPERIMENTAL
Intervention: Crosseal (2 mL sprayed under the skin flap)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Crosseal (treated side)
Number of subjects: 9
Study: 17362570

Group type: EXPERIMENTAL
Intervention: Self-sampling HPV test
Number of subjects: 920

Group type: COMPARATOR
Intervention: Clinician HPV test
Number of subjects: 920

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 920
Study: 15302637

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d for 10 days
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 121
Study: 15532006

Group type: EXPERIMENTAL
Intervention: Stepwise protocol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rampwise protocol
Number of subjects: 14
Study: 10193720

Group type: EXPERIMENTAL
Intervention: Paroxetine at 20 mg once a day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 68
Study: 8520811

Group type: EXPERIMENTAL
Intervention: MID 10 mg + 150 mg fluconazole (FLU)
Number of subjects: 5

Group type: COMPARATOR
Intervention: MID 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MID 10 mg after FLU
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MID 10 mg after 750 mg erythromycin (ERY)
Number of subjects: 5

Group type: COMPARATOR
Intervention: MID 10 mg alone
Number of subjects: 5
Study: 2271746

Group type: EXPERIMENTAL
Intervention: Midaglizole 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midaglizole 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midaglizole 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midaglizole 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midaglizole 200 mg (30 min after breakfast)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midaglizole 200 mg t.i.d. (20 min before meals for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midaglizole (all doses)
Number of subjects: 0
Study: 7416592

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 mg of naloxone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion of normal saline
Number of subjects: 6
Study: 31831920

Group type: COMPARATOR
Intervention: Mupirocin 2%
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mupirocin 2% and Sucralfate 7% combination
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 27379961

Group type: COMPARATOR
Intervention: Midcooling (facial water spray and menthol mouth rinse)
Number of subjects: 11

Group type: COMPARATOR
Intervention: All methods combined (PRE, MID, ALL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Precooling (cold-water immersion and ice slurry ingestion)
Number of subjects: 11

Group type: COMPARATOR
Intervention: All conditions (PRE, MID, ALL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Midcooling
Number of subjects: 11

Group type: COMPARATOR
Intervention: Precooling
Number of subjects: 11
Study: 25697494

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3060

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 3060

Group type: COMPARATOR
Intervention: Control (lowest risk quarter)
Number of subjects: 3060
Study: 25050898

Group type: EXPERIMENTAL
Intervention: Resistance training (INT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls (REF)
Number of subjects: 30
Study: 22520674

Group type: EXPERIMENTAL
Intervention: Algorithm for estimating absolute risk of pancreatic cancer
Number of subjects: 375
Study: 19265095

Group type: EXPERIMENTAL
Intervention: Urgent direct current cardioversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic drugs (flecainide, propafenone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmic drug (amiodarone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta blockers and rate limiting calcium blockers, digoxin
Number of subjects: 0
Study: 17376187

Group type: EXPERIMENTAL
Intervention: Polyglactin sutures
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 32
Study: 15383112

Group type: EXPERIMENTAL
Intervention: Bipolar radio-frequency ablation (NovaSure)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Balloon ablation (ThermaChoice)
Number of subjects: 126
Study: 11522497

Group type: EXPERIMENTAL
Intervention: epalrestat (150 mg/day) for 5 years
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 9640123

Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion of Propofol
Number of subjects: 562

Group type: COMPARATOR
Intervention: Manually Controlled Infusion of Propofol
Number of subjects: 562
Study: 7973776

Group type: EXPERIMENTAL
Intervention: Amifostine (Ethyol)
Number of subjects: 0
Study: 30321960

Group type: EXPERIMENTAL
Intervention: Weil osteotomy (WO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distal metatarsal metaphyseal osteotomy (DMMO)
Number of subjects: 60
Study: 28454526

Group type: EXPERIMENTAL
Intervention: Preservative-free 0.0015% tafluprost (NPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preservative containing 0.0015% tafluprost (PT)
Number of subjects: 20
Study: 26188896

Group type: EXPERIMENTAL
Intervention: Continuous infusion of procaine 0.5% at 4-5 ml/h for 48 hours via elastomeric pump
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard post-operative pain regimen of metamizole 1 g and/or ketorolac 3% - 30 mg
Number of subjects: 109
Study: 24622000

Group type: EXPERIMENTAL
Intervention: Post-discharge heart rate ≥70 beats/min
Number of subjects: 1947
Study: 20652857

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Miniprobe EUS
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Radial EUS
Number of subjects: 955
Study: 17237328

Group type: EXPERIMENTAL
Intervention: Combined iron (10 mg) and zinc (10 mg) supplementation for 6 months
Number of subjects: 2468

Group type: EXPERIMENTAL
Intervention: Iron (10 mg) supplementation for 6 months
Number of subjects: 2468

Group type: EXPERIMENTAL
Intervention: Zinc (10 mg) supplementation for 6 months
Number of subjects: 2468

Group type: COMPARATOR
Intervention: Vitamin A capsules (VAC) administration
Number of subjects: 2468
Study: 15689350

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (UG-ET)
Number of subjects: 67
Study: 11975390

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10436401

Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy (PTX) without autotransplantation in hemodialysis patients (group I)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy (PTX) without autotransplantation in patients without renal insufficiency (group II)
Number of subjects: 16
Study: 7786974

Group type: EXPERIMENTAL
Intervention: Relaxation therapy combined with anti-depressive medication
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group receiving only anti-depressive medication
Number of subjects: 31
Study: 1972349

Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg twice daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 119258

Group type: EXPERIMENTAL
Intervention: +amphetamine (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +/-fenfluramine (30 mg and 60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 31888711

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 28507353

Group type: EXPERIMENTAL
Intervention: Ketamine-Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketamine-Dexmedetomidine
Number of subjects: 60
Study: 25731132

Group type: EXPERIMENTAL
Intervention: Self-management intervention targeting cognitive dysfunction, including education on cognitive function, self-awareness training, compensatory strategies, and problem-solving therapy; formal working memory training in a subgroup.
Number of subjects: 16
Study: 24083804

Group type: EXPERIMENTAL
Intervention: eplerenone (target dose 50mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 130
Study: 21242700

Group type: EXPERIMENTAL
Intervention: Acute resistance exercise protocol (6 sets of 5 repetition maximum heavy squats)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control test
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute resistance exercise protocol
Number of subjects: 15
Study: 19513028

Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bipolar Electrocoagulation (BPEC)
Number of subjects: 45
Study: 18372688

Group type: EXPERIMENTAL
Intervention: Intermittent artificial gravity (AG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no artificial gravity)
Number of subjects: 15
Study: 14691037

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Bare stents (pre-SES group)
Number of subjects: 958
Study: 12153921

Group type: EXPERIMENTAL
Intervention: Trials funded by for profit organisations alone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Trials without competing interests
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Trials funded by both for profit and non‐profit organisations
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Trials with other competing interests
Number of subjects: 159

Group type: COMPARATOR
Intervention: Other competing interests and funding from both for profit and non‐profit organisations
Number of subjects: 159
Study: 9833847

Group type: COMPARATOR
Intervention: 100 mg abacavir twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 mg abacavir twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 600 mg abacavir twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 mg abacavir + zidovudine + lamivudine (open-label phase)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All abacavir-treated subjects (pooled data)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abacavir (overall safety)
Number of subjects: 60
Study: 8135426

Group type: EXPERIMENTAL
Intervention: IV phenytoin (15 mg/kg over 20 minutes)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Normal saline placebo (equivalent volume over 20 minutes)
Number of subjects: 147
Study: 2552625

Group type: EXPERIMENTAL
Intervention: RBCs stored 3 to 8 days
Number of subjects: 166

Group type: COMPARATOR
Intervention: RBCs stored 20 to 42 days
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Seronegative RBCs
Number of subjects: 166

Group type: COMPARATOR
Intervention: Random RBCs
Number of subjects: 166
Study: 162671

Group type: EXPERIMENTAL
Intervention: diclofenac sodium
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 31642694

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA) with standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 30695668

Group type: EXPERIMENTAL
Intervention: Adjuvant Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 0
Study: 28027625

Group type: EXPERIMENTAL
Intervention: Everolimus (n = 359)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Calcineurin Inhibitor (CNI) (n = 356)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Tacrolimus (part of CNI group)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Cyclosporine (part of CNI group)
Number of subjects: 715
Study: 25932981

Group type: EXPERIMENTAL
Intervention: TOTAL (3 days per week using a total-body routine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SPLIT (1 day per week using a split-body routine)
Number of subjects: 20
Study: 24500150

Group type: EXPERIMENTAL
Intervention: MFGM-supplemented, low-energy, low-protein experimental formula (EF)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Breastfed reference (BFR) group
Number of subjects: 240
Study: 22929331

Group type: EXPERIMENTAL
Intervention: Pulmonary perifissural nodules (PFNs) identified via CT scans
Number of subjects: 2994
Study: 19957560

Group type: EXPERIMENTAL
Intervention: Betaferon 8MIU subcutaneously every other day (Group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Betaferon with a reduced dosage regimen (2 MIU, 4 MIU, and 8 MIU) subcutaneously, varying by week (Group B)
Number of subjects: 55
Study: 17601993

Group type: EXPERIMENTAL
Intervention: Acipimox treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 16366421

Group type: EXPERIMENTAL
Intervention: HCA-SX 4,667 mg (providing 2,800 mg HCA per day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of HCA-SX 4,667 mg, niacin-bound chromium (NBC) 4 mg, and Gymnema sylvestre extract (GSE) 400 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12228880

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unclassified group
Number of subjects: 0
Study: 9476870

Group type: EXPERIMENTAL
Intervention: Peak Flow Monitoring (PFM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Symptoms Group
Number of subjects: 92
Study: 7624991

Group type: EXPERIMENTAL
Intervention: Goserelin, 3.6 mg every 28 days
Number of subjects: 283

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 283
Study: 2793646

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 189
Study: 343863

Group type: EXPERIMENTAL
Intervention: Arginine for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 64
Study: 29363136

Group type: EXPERIMENTAL
Intervention: Finisher GF Brush (GB)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Syringe-and-needle irrigation (SNI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (untreated canals)
Number of subjects: 72
Study: 27343785

Group type: EXPERIMENTAL
Intervention: GlideScope™ visualization
Number of subjects: 96

Group type: COMPARATOR
Intervention: MacIntosh laryngoscope assistance
Number of subjects: 96
Study: 24507744

Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Non-surgical ablation (non-SA)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: History of myocardial infarction
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Higher EuroSCORE
Number of subjects: 194
Study: 22278004

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other psychotherapeutic methods
Number of subjects: 0
Study: 20155571

Group type: EXPERIMENTAL
Intervention: Adapted to deep water running
Number of subjects: 17

Group type: COMPARATOR
Intervention: Not adapted to deep water running
Number of subjects: 17

Group type: COMPARATOR
Intervention: Treadmill running
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Deep water running
Number of subjects: 17
Study: 18621453

Group type: EXPERIMENTAL
Intervention: 12-week biomechanical ankle platform system training
Number of subjects: 12